On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.

This interim analysis showed a robust neutralizing antibody response in both age groups after a 25 ﾵg two-dose primary series of mRNA-1273 along with a favorable safety profile.